- Alumis anticipates **Phase 3 psoriasis data** for its lead asset, **ESK-001**, in **early Q1 2026**, with **Phase 2b lupus data** expected in **Q3 2026**.  **[1847367_2145713_0]** 
- The company's cash runway is projected to extend into **2027**, supported by the Acceleron merger, covering key clinical readouts.  **[1847367_2145713_0]** 
- **ESK-001** is positioned as a differentiated TYK2 inhibitor, capable of achieving **high target inhibition** without the dose-reduction issues observed with some other molecules.  **[1847367_2145713_1]** 
- Alumis is also advancing **A-005**, a brain-penetrant TYK2, into **Phase 2 for MS**, and has **lonigutamab** and an **IRF5 program** with Phase 1 data anticipated in 2026.  **[1847367_2145713_0]** **[1847367_2145713_5]** **[1847367_2145713_6]**

Alumis Provides Update on Clinical Pipeline and Financial Runway

- Alumis Inc. expects **Phase 3 psoriasis read-out in early Q1 next year** and **pivotal Phase 2b lupus read-out in Q3 next year**.  **[1847367_tx_381232_0]**  The company plans to **file for psoriasis in 2026**.  **[1847367_tx_381232_4]** 
- The company reported **$486 million in cash and cash equivalents** at the end of the second quarter, providing a **cash runway into 2027**.  **[1847367_tx_381232_7]**  R&D expenses are expected to **significantly decrease in the second half of this year**.  **[1847367_tx_381232_7]** 
- Alumis is unlikely to launch its drug, Envutucitinib (Envu), globally independently and is considering **partnerships**.  **[1847367_tx_381232_4]**  A **once-a-day formulation** of Envu is planned within the first year of launch.  **[1847367_tx_381232_4]** 
- A **Phase 2 trial for A-005**, a brain-penetrant TIK2 inhibitor, in MS is set to begin in the **first half of next year**.  **[1847367_tx_381232_6]**

ALUMIS (ALMS)